admin

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response

News / By

This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype.  NORTH BRUNSWICK, N.J., September 28, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown …

September 2021: Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response Read More »

Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages

Publication / By

Reshma Kumari Sharma, Binita Goswami, Sukhen Das Mandal, Abhishek Guha, Belinda Willard and Partho Sarothi Ray (2021, August 6). Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in MacrophagesJ Immunol August 6, 2021, ji2001392; DOI: https://doi.org/10.4049/jimmunol.2001392 Abstract Quorum-sensing mechanisms that sense the density of immune cells at the site of inflammation to initiate inflammation resolution have recently been …

Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages Read More »

August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

News / By

Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., August 27, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a case study, Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized …

August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient Read More »

June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection

News / By

NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced that it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant …

June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection Read More »

Financial Analyst – Biotech

Jobs / By

FINANCIAL ANALYST – BIOTECH The Financial Analyst reports to the COO and works closely with other Senior Management.  Key areas of focus are: assisting with the consolidated financials and forecasts/budgets working with corporate accounting personnel to ensure proper expense recognition and compliance with internal controls. all aspects of fundraising for this private company working cross-functionally …

Financial Analyst – Biotech Read More »

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist

News / By

This distinguished awards program celebrates the unstoppable entrepreneurs whose unbounded ambitions deliver innovation, growth and prosperity that transform our world.   NORTH BRUNSWICK, N.J., June 4, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announces …

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist Read More »

April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases

News / By

Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 8, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio …

April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases Read More »

March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

News / By

MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced today that it has completed enrollment for its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’ …

March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More »

March 2021: BioAegis CEO, Dr. Susan Levinson, appointed to BioNJ Board

News, Uncategorized / By

We are excited to announce that BioAegis Chief Executive Officer, Dr. Susan Levinson, has been appointed to the BioNJ Board of Directors.  BioNJ is the life sciences trade association for New Jersey with nearly 400 Member companies representing research-based life sciences organizations and stakeholders across the ecosystem from the largest biopharmaceutical companies to early stage start-ups.  BioNJ is …

March 2021: BioAegis CEO, Dr. Susan Levinson, appointed to BioNJ Board Read More »

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Publication / By

An immune-based biomarker signature is associated with mortality in COVID-19 patients. (2020, November 24). Https://Insight.Jci.Org/Articles/View/144455. https://insight.jci.org/articles/view/144455 Abstract Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels …

An immune-based biomarker signature is associated with mortality in COVID-19 patients Read More »

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

Clinical Trials Arena Award -
Best Covid 19 Response
February 2021

EVENTS

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

 

JOIN OUR TEAM

 

PRODUCT FAQS

FOLLOW US

Twitter Linkedin Youtube Medium

©2022 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use